On October 29, 2020 Concure Oncology, whose mission is to ease the burden for women facing early-stage breast cancer by providing an innovative new kind of radiation treatment option, reported that it has secured another $2 million in capital, showing continued momentum for the treatment that has been giving new hope to women battling breast cancer (Press release, Concure Oncology, OCT 29, 2020, View Source [SID1234569432]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This additional round of funding will allow Concure to further grow its organization and train new clinicians across the country to bring this treatment option to even more women. It follows an earlier $2 million that was raised in March and company growth in 2019 when Concure expanded its high-profile team of clinical experts in breast cancer treatment, and brings the company’s new funding to $4 million within the last 9 months, a time period that has been very difficult for early-stage medical device companies.
"This additional financing speaks to the excitement and momentum we’ve been seeing for this truly groundbreaking type of breast cancer therapy," said Scott Armstrong, chief executive officer of Concure Oncology. "With this funding, we can build out our team and give women facing breast cancer a better and more effective form of treatment as we move forward."
Breast Microseed Treatment is safe, effective and convenient in providing radiation therapy to patients with early-stage breast cancer. This technique, also known as low-dose-rate brachytherapy, is based on a similar method that has already been proven to successfully treat prostate cancer. What distinguishes this treatment from conventional radiation therapy is that it allows post-lumpectomy patients the chance to have a one-time, one-hour procedure, as opposed to the more burdensome conventional radiation that may last from three to six weeks and require daily visits to a radiation facility.
Concure Oncology’s treatment has been recognized as being as effective as traditional whole breast irradiation relative to local recurrence and overall survival rates, with excellent cosmetic outcomes as well as reported high patient satisfaction levels in peer-reviewed, published data. The procedure involves the placement of tiny, low dose-rate brachytherapy sources – or Microseeds – into the breast tissue, which release a safe but effective dose of radiation for 2-3 months to the immediate area surrounding the lumpectomy site. Once fully released, the seeds become inert, with no radioactivity remaining.
Individuals interested in clinical applications, sales or marketing roles at Concure should visit the company’s website for more information.